Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co, Inc. (MRK) Management Presents at Guggenheim Biopharma Strategy Series Conference Call (Transcript)

Apple

Coca-Cola

Procter & Gamble

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

While Berkshire Hathaway Inc. (NYSE: BRK-B) doesn't own most of the 30 equities in the Dow Jones Industrial Average, more than half of the eight Dow stocks that Warren Buffett and Berkshire do own are trading down year to date.

The 5 Poor Performing Dow Stocks in Warren Buffett's Portfolio

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of OS & PFS in Patients With Persistent, Recurrent or Metastatic Cervical Cancer

Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer

Zoetis

Zoetis stock has risen 2x from levels of $92 that it was at on March 23, 2020, when broader markets made a bottom, to levels of $184 now, while Merck's stock has underperformed and gained only 26% of its value. Looking at valuation, Merck stock trades at about 4x trailing revenues, compared.

Does The Valuation Gap Between Merck Stock And Zoetis Make Sense?

Merck/Ridgeback Bio partnership on tablet form of antiviral molnuparivir attracts US Government interest for early-stage COVID treatment.

Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack

Thor Industries

Vertex Pharmaceuticals

Analyst 12-month price targets are the educated guesstimates that many obsess over, and can result in wild short-term price swings. According to JPMorgan, 94% of 12-month returns are luck, which is why I never base investment decisions on 12-month price targets.

3 Blue-Chip Bargains That Could Soar 20+% In The Next Year

Bristol-Myers

British American Tobacco

Enterprise Products Partners

Lockheed Martin

Magellan Midstream Partners

Norsk Hydro ASA

Orange

6 Investments With 14-20% Annual Upside

U.S. government commits to purchase approximately 1.7 million courses of Molnupiravir upon issuance of Emergency Use Authorization or approval by the U.S. Food and Drug Administration KENILWORTH, N.J., June 17, 2021 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has entered into a procurement agreement with the United States government for Molnupiravir (MK-4482).

MSD Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19

Coronavirus prevention goes beyond vaccines.

This Biopharma Giant May Have Just Found Its Ticket To Riches In the COVID-19 Market

AbbVie

General Motors

Sirius XM Holdings Inc

StoneCo

Suncor Energy

U.S. Bancorp

On Wednesday, we took a look at five of the 13 stocks in which Warren Buffett lightened or sold entirely Berkshire Hathaway Inc.

Warren Buffet Sold These 8 Stocks in Q1 and All Have Done Well in Q2

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Guggenheim Biopharma Strategy Series

Merck to Participate in the Guggenheim Biopharma Strategy Series

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress towards Improved Birth Outcomes for All

Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress towards Improved Birth Outcomes for All

MRK stock might not be an obvious "vaccine stock," but Merck's commitment to combating Covid-19 is commendable and potentially profitable. The post Hold Merck for Its Solid Dividend and Covid-19 Treatment Prospects appeared first on InvestorPlace.

Hold Merck for Its Solid Dividend and Covid-19 Treatment Prospects

Janux Therapeutics

The 37th biotech to hit the public markets this year has a potentially $1 billion deal with Merck & Co. Inc. ( MRK , Financial).

Merck Partners With Newly Public Cancer Biotech

AstraZeneca

Freeport-McMoRan

Starbucks

West Fraser Timber Co. Ltd.

Walmart

Shares don't always rise, but dividend income is as steady as it gets. These dividend stocks are great long-term, despite recent weaknesses.

7 Dividend Stocks Offering Juicy Yields and Short-Squeeze Potential

Merck is the world's seventh largest pharmaceutical company, has an A+ credit rating and has raised the dividend for ten consecutive years. The 130-year-old company has a new leadership team and a streamlined profile after spinning off some legacy businesses.

Dividend Sleuthing: Merck

AmerisourceBergen

Chewy

Covetrus Inc

Elanco Animal Health Inc

Freshpet

General Mills

Heska

IDEXX Laboratories

Nestle SA

Proshares Pet Care ETF

Patterson Companies

PetIQ

J. M. Smucker

Unicharm Corp

Petco Health and Wellness

Zomedica

The physiological and psychological benefits that pets give us are meaningful. COVID has amplified our appreciation of this. Anticipating 6% annual growth until 2030 may be conservative, even across developed markets.

Overview Of Opportunities In Animal Companionship: A $200B Industry Growing At 6.1% Annually

Chevron

Dow Inc

It is hard to believe, but in just over three weeks the second quarter will come to a close and many investors will be reviewing their portfolios and making changes for the second half of 2021.

Why the 5 Highest-Yielding Dow Stocks Are Great Second-Half Buys

Merck (MRK) is set to supply 1.7 million courses of its oral COVID-19 therapy candidate, molnupiravir, worth $1.2 billion to the U.S. government, following a potential approval or authorization.

Merck (MRK) Signs $1.2B Deal With US for COVID-19 Therapeutic

GlaxoSmithKline

Viatris

Attractive dividends plus strong growth? Yes, please.

3 Dividend Stocks Wall Street Thinks Will Soar 20% or More

The U.S. government will pay $1.2 billion for 1.7 billion doses of Merck's experimental oral COVID-19 drug.

Merck Cuts a Billion-Dollar COVID Deal

Merck & Co Inc (NYSE: MRK) has entered into a procurement agreement with the U.S. government for molnupiravir (MK-4482), an antiviral candidate for mild to moderate COVID-19. Molnupiravir is currently being evaluated in Phase 3 MOVe-OUT study to treat non-hospitalized patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes.

Merck Inks Molnupiravir Supply Pact With US Government For COVID-19

Shares of Merck & Co. Inc. rose 0.9% in premarket trading Wednesday, after the drug maker announced a supply agreement with the U.S. government for molnupiravir, its investigational oral antiviral candidate to treat mild to moderate COVID-19. Molnupiravir is currently undergoing a Phase 3 clinical trial for treating COVID-19 in non-hospitalized patients with at least one risk factor.

Merck enters $1.2 billion agreement to supply U.S. government with potential COVID-19 treatment

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Supply Agreement with U.S. Government for Molnupiravir

Merck Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19

Merck & Co., Inc. (MRK) Management Presents at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting Conference (Transcript)

News for Merck Stock (MRK)